What’s Propelling Compugen Limited (NASDAQ:CGEN) After Higher Shorts Reported?

December 23, 2017 - By Michael Collier

 What’s Propelling Compugen Limited (NASDAQ:CGEN) After Higher Shorts Reported?

The stock of Compugen Limited (NASDAQ:CGEN) registered an increase of 8.31% in short interest. CGEN’s total short interest was 2.27M shares in December as published by FINRA. Its up 8.31% from 2.10 million shares, reported previously. With 136,900 shares average volume, it will take short sellers 17 days to cover their CGEN’s short positions. The short interest to Compugen Limited’s float is 4.93%.

It closed at $2.8 lastly. It is down 29.94% since December 23, 2016 and is downtrending. It has underperformed by 46.64% the S&P500.

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company has market cap of $143.20 million. The companyÂ’s pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. It currently has negative earnings. The Company’s antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target.

Compugen Ltd. (NASDAQ:CGEN) Ratings Coverage

Among 5 analysts covering Compugen (NASDAQ:CGEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Compugen had 8 analyst reports since August 5, 2015 according to SRatingsIntel. Zacks upgraded the shares of CGEN in report on Friday, August 21 to “Sell” rating. The firm earned “Outperform” rating on Thursday, October 15 by FBR Capital. Oppenheimer maintained the stock with “Buy” rating in Wednesday, August 5 report. The company was maintained on Wednesday, March 9 by JMP Securities. On Thursday, October 15 the stock rating was initiated by Cowen & Co with “Outperform”. Zacks upgraded the shares of CGEN in report on Wednesday, September 2 to “Hold” rating. The rating was maintained by MLV on Wednesday, August 5 with “Buy”.

More notable recent Compugen Ltd. (NASDAQ:CGEN) news were published by: Prnewswire.com which released: “Compugen Immune Checkpoint Program Demonstrates Potential for Development of …” on November 11, 2016, also Prnewswire.com with their article: “Compugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program” published on February 29, 2016, Benzinga.com published: “28 Stocks Moving In Monday’s Pre-Market Session” on October 09, 2017. More interesting news about Compugen Ltd. (NASDAQ:CGEN) were released by: Prnewswire.com and their article: “Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew …” published on April 06, 2016 as well as Seekingalpha.com‘s news article titled: “Compugen’s (CGEN) CEO Anat Cohen-Dayag on Q3 2017 Results – Earnings Call …” with publication date: November 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.